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Summary Twenty-three patients with advanced NSCLC were treated with high dose chemotherapy using four
agents and autologous bone marrow reinfusion. Ten patients received two bolus doses of cyclophosphamide
(maximum tolerated total dose 10 G m 2), ifosfamide as a 24 h infusion (11 G m-2) followed by mitomycin C
(70 mg m 2) as a subsequent 24h infusion and mustine as two boluses (total dose 30 mg m 2). Another 13
patients received the same agents except cisplatin was substituted for cyclophosphamide, two doses (total dose
100 mg m 2) being given in a 24 h period. The median time of recovery to >20,000 platelets was 21 days and
of neutropaenia > 500 was 12-15 days. Unusual non-haematological toxicity e.g. cardiomyopathy, colitis,
veno occlusive disease was not noted, all patients being given regular selenium and other trace elements. Three
patients died in the first 2 weeks. There were five complete responses (22%) and 12 partial responses (52%)
with four patients (2CR, 2PR) still alive at 27, 48, 73 and 82 weeks. The patient's Karnofsky performance in
the cisplatin regimen improved over pretreatment values when compared a month after the end of treatment.
The high dose regimen was associated with a high (74%) response rate, but with an overall median survival of
only 6 months. The regimen has no advantage over conventional doses with the same agents in patients with
metastatic NSCLC.
Single agent tumour responses rates in advanced non small
cell lung cancer (NSCLC) are of the order of 20%, even with
the most active agents - ifosfamide, cisplatin, mitomycin C.
Complete responses are rare (Bakowski & Crouch, 1983).
Other alkylating agents - mustine and cyclophosphamide are
also active and high dose cyclophosphamide has an enhanced
response even in patients refractory to standard doses (Sela-
wry, 1982; Thatcher et al., 1988; Slease et al., 1988; Frei et
al., 1989).
Alkylating agents and cisplatin exhibit steep dose response
curves in experimental systems, and clinical data indicate a
similar relationship (Frei, 1979; Frei & Canellos, 1980).
There is further evidence both in vitro and in vivo that
non-cross resistance occurs between alkylating agents (Scha-
bel et al., 1978; Teicher et al., 1986). High dose combination
alkylating agent therapy is therefore attractive, particularly
as the major dose limiting toxicity of these agents is myelo-
suppression which can be ameliorated by autologous bone
marrow re-infusion (ABMR).
Materials and methods
Patients
Twenty-three patients with histologically proven NSCLC
were entered into the study from March 1986 to March 1988.
There were seven female and 16 male patients with a median
age of 40 years. All patients had Stage IlIb disease or greater
(Mountain, 1986). Ipsilateral supraclavicular (SCF) lymph-
adenopathy was present in four patients, contralateral SCF
nodes in two patients and pleural effusions in seven patients.
All patients were unsuitable for radical radiotherapy or resec-
tion, the patient characteristics are described in Table I.
Patient consent was obtained after explanation of the high
dose regimen, supportive measures and toxicity likely to be
encountered. All patients had to have pre-treatment Kamof-
sky scores of 50 or more, adequate pre-treatment bone mar-
row function (WBC> 3 x I091, platelet count> 100x 1091)
and normal bone marrow aspirate and trephine. In addition
patients older than 55 years of age, those with other medical
conditions which would make the high dose treatment un-
duly dangerous, and those with cerebral metastases were
excluded from the study. Twenty-two patients had received
no previous treatment, the other patient had developed recur-
rence following lobectomy.
Pre-treatment evaluation
Patients were assessed by routine history, clinical examina-
tion, routine blood counts, hepatic, renal biochemistry and
chest radiography. Pre-treatment bone marrow aspirate
examination and CT scanning of the thorax, brain and abdo-
men were performed.
Bone marrow harvest and chemotherapy regimen
Before chemotherapy a subclavian vein central catheter was
inserted followed by bone marrow harvest. Partial anti-
coagulation was achieved with 3-5,000 units of preservative
free heparin. Bone marrow aspirates from the posterior iliac
crest and sternum were stored at 4°C in (75 ml) acid citrate
dextrose (Thatcher et al., 1989). All patients had the marrow
harvested under general anaesthesia. An average of 600 ml of
marrow was collected and a median of 2.49 x 109 (range 1.17
to 5.97) nucleated cells per kilogram obtained. Bone marrow
was re-infused 56 h after start of treatment, i.e. 8 h after the
end of treatment.
Chemotherapy was given as in the diagram. For ifosfamide
and mitomycin C a loading dose of each drug (25-30% of
the total dose) was given over the first hour of the 24 h
infusion. In the first ten patients cyclophosphamide was given
as a bolus at 8 and 16 h after the start of the ifosfamide and
mesna (24 h) infusion. Cisplatin with mannitol diuresis and
electrolytes were substituted for cyclophosphamide in the
other 13 patients after noting the low CR rate with the
cyclophosphamide regimen.
All patients were well hydrated before and during chemo-
therapy with at least 3 litres m-2 of normal saline and dex-
trose-saline given intravenously over a period of 6 h. Further
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Table I Patients' characteristics
Regimen A
Tumour stage Cyclosphos-
Histology and (TNM) with phamide Ifosfamide
Pt Age KPS differentiation M site G m-2 G m2
1 34 90 Squamous cell T4N3Mo 3.0 7.0
moderate to well
diff.
2 51 70 Squamous cell
moderate to well
diff.
3 44 80 Adenocarcinoma
poorly diff.
4 42 80 Squamous cell
poorly diff. bo
5 31 80 Squamous cell
moderate to well
diff.
6 42 90 Adenocarcinoma
poorly diff.
7 22 90 Large cell
anaplastic
8 38 60 Adenocarcinoma
poorly diff.
9 47 50 Squamous cell
moderate to well
diff.
10 41 70 Squamous cell
poorly diff.
axi
Mustine
mgM-2
20.0
T4N2MO 3.5 8.0 20.0
T4N3Mo 4.0 9.0 25.0
T4N3M1 4.0 9.0 25.0
ne,pulmonary
T4N3Mo 4.0 7.0 25.0
T3N3Mo 4.0 10.0 25.0
T3N3MI 4.0 10.0 25.0
illary nodes
T4N3MO 4.0 10.0 30.0
T4N2M0 4.0 10.0 30.0
T4N3Mo 5.0 11.0 30.0
Mitomycin Survival
mg m-2 Response (weeks)
50.0 PR 20
50.0 PR 28
60.0 NR 2
60.0
60.0
60.0
PR 24
PR 77
CR 38
60.0 Stable 78
70.0 CR 18
70.0 NR 2
70.0 PR 18
Regimen B
11 41 70 Squamous cell T4NIMO 80.0
poorly diff.
12 40 70 Squamous cell T4N2Mo 80.0
moderate to well
diff.
13 44 60 Adenocarcinoma T4N2MI 85.0
poorly diff. Liver
14 44 70 Sqamous cell T4N2Mo 85.0
moderate to well
diff.
15 39 80 Squamous cell T4N3MI 100.00
poorly diff. abdominal
nodes pulmonary
16 44 70 Squamous cell T4N3Mo 100.0
moderate to well
diff.
17 35 80 Adenocarcinoma T4N3Mo 100.0
moderately diff.
18 40 60 Squamous cell T4N2M1 100.0
moderate to well Bone
diff.
19 39 90 Squamous cell T4N2MO 100.0
poorly diff.
20 37 70 Squamous cell T4N2Mo 100.0
moderate to well
diff.
21 40 90 Squamous cell T4N2MO 100.0
moderate to well
diff.
22 34 70 Squamous cell T4N1MO 100.0
poorly diff.
23 46 90 Adenocarcinoma T4NOMO 100.0
8.0 20.0
8.0 20.0
8.0 20.0
8.0 20.0
8.0 25.0
9.0 20.0
9.0 20.0
10.0 20.0
10.0 20.0
10.0 20.0
10.0 20.0
10.0 20.0
10.0 25.0
50.0 CR 48**
50.0 PR 30
50.0 NR 2
50.0
60.0
PR 27*
PR 5
60.0 CR 25
60.0 NR 16
60.0
60.0
60.0
60.0
PR 32
PR 48
PR 29
PR 73*
60.0 NR 16
70.0 CR 82**
KPS-Karnofsky performance score; CR-Complete response; PR-Partial response; NR-No response; `Alive no tumour; Alive
with tumour.
fluid was given as required to obtain a satisfactory urine Supportive care
output of 150 ml per hour. The drug dosages were escalated
and the total dosages delivered are shown in Table I. All Immediately after the end of chemotherapy, intravenous
patients received regular metoclopramide and chlorpromazine trace elements and high potency B and C multivitamin com-
for the first 48 h of chemotherapy. plex (Parentrovite) were given for 48 h. The trace elementHIGH DOSE CHEMOTHERAPY FOR NSCLC 295
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Figure 1 Treatment plan
support (McCarthy's) was given in two solutions. The first
consisted of copper 1.6mg, chromium 5 ig and selenium
120 jig in 1.1 ml which was given 12 hourly for four doses.
The second solution consisted of zinc (1 mgml1) in a total
dose of 10mg, given at the same frequency and duration.
Monitoring of blood counts, biochemistry, antibiotic admin-
istration with leucopaenia < 1,000 x 1061 cells and prophyl-
actic platelet transfusion for thrombocytopaenia (<20 x
i091) were similar to our high dose study in melanoma
(Thatcher et al., 1989).
Treatment evaluation
Response was determined by repeat clinical, laboratory and
radiology (including CT scanning) investigations 4 to 6 weeks
after the start of chemotherapy and defined according to
standard WHO criteria (Monfardini et al., 1981).
Duration of response was taken from the data of treatment
to relapse. Haematological and non haematological toxicity
were graded according to standard WHO criteria (Monfar-
dini et al., 1981), except for gastro-intestinal toxicity (Table
III) which was graded according to Leff et al. (1986). The
Karnofsky score and MRC respiratory score, a measure of
breathlessness was assessed before and at regular intervals
after treatment (MRC Lung Cancer Working Party, 1979).
Results
Response and survival
Seventeen out of the total of 23 patients responded to treat-
ment 74% (95% confidence limits 52-90%). Of these five
22% (95% confidence limits 7-44%) were complete respon-
ders as assessed by repeat CT scan. The median survival of
the total group of patients was 6 months range < 1-20.5 +
months, see Table I.
Seven of the ten patients responded with the quadruple
regime which included cyclophosphamide (regimen A) with
two complete responders. However, no patient in this group
survived longer than 18 months (Table I). Responses occur-
red in the primary lung tumour, mediastinal and peripheral
nodes, although bone and the pulmonary metastases also
responded. Median duration of response was 12 weeks (range
7-31 weeks). With the cisplatin combination (regimen B),
responses were mainly in the primary tumour and medias-
tinum, but also in bone and nodal metastases. Median dura-
tion of response was 32 weeks (range 7-80 + weeks). Three
patients (all in the regimen B group) are still alive, two who
continue in complete response and one in PR, see Table I.
There was no statistically significant difference in survival
between the two treatment regimens (P = 0.62). The median
survival with the cyclophosphamide, regimen (A) was 20
weeks (range 2-78) and with the cisplatin regimen (B) 30
weeks (range 2-82+).
All patients have been evaluated for toxicity. The haema-
tological toxicity and blood count recovery times are shown
in Table II. There was no significant difference between the
two regimens, nor was there any obvious difference in the
requirement for supportive care. The vast majority of
patients were able to be discharged 3 to 4 weeks after start of
treatment. There was considerable gastrointestinal distur-
bance in the first 2 weeks of treatment (Table III). The main
problem was stomatisis, particularly in the second and third
week, and this was associated with altered taste sensation for
up to 2 months after treatment. Despite the considerable
non-haematological toxicity the patients' Karnofsky perfor-
mance scores remained fairly stable and breathlessness
improved particularly with the cisplatin regimen (Tables IV
and V).
Two patients in the cyclophosphamide group and one
patient in the cisplatin group died 2 weeks after starting
treatment. The latter patient had renal failure and tumour
involvement of the kidneys at autopsy. In the cyclophospha-
mide group one patient at post-mortem had a subdural
haematoma, intracerebral haemorrhage with petechial haem-
orrhages in the stomach, duodenum and small bowel in the
absence of pancytopenia or any clotting defect. The second
patient developed increasing dyspnoea but at post mortem
Table II Haematological toxicity
Regimen A Regimen B
with Cyclophos-
phamide with Cisplatin
x 1O6 l- Median value and range in days
Time to:
Leucopenia < 1,000 7 (6-10) 8 (6-9)
Recovery > 1,000 14 (10-19) 17 (12-21)
Neutropenia < 500 7 (6-9) 8 (6-9)
Recovery > 500 12 (4-17) 15 (11-17)
Thrombocytopenia < 50,000 8 (6-14) 10 (8-11)
Recovery >50,000 21 (19-35) 21 (13-25)
Recovery .20,000 10 (8-17) 10 (2-15)
>20,000 20 (14-25) 20 (16-23)
Number of platelet
transfusions 16 (4-66) 15 (0-42)
Days of i.v. antibiotics 11 (0-18) 13 (4-21)
Days of hospitalisation 23 (14-45) 22 (8-53)
I
I _ _ _ I~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
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Table III Non-haematolgical toxicity
Number of patients with toxicity grade >2
Regimen A with Regimen B
cyclophosphamide with Cisplatin
No patients 10 13
Nausea and vomiting
Week 1 9 9
2 5 7
3 3 2
4
Stomatitis
Week 1 - 2
2 4 3
3 3 2
4
Diarrhoea
Weeki 1 3
2 4 4
3 2
4
Lethargy (> 50% waking hours)
Week 1 9 9
2 5 3
3 2 1
4
Gastrointestinal Toxicity Criteria (Leff et al., 1986).
Toxicity criteria
Grade Emesis stomatitis/esophagitis Diarrhoea
1. Mild 1-3 Pain without ulceration; able to Watery stools, <6
episodes eat most foods stools per day
per day
2. Moder- 4-10 Same as severe toxicity, but less 6-12 stools per
ate episodes than 14 days duration day
3. Severe More than Painful ulceration with inanition Hemorrhagic enter-
10 episodes requiring narcotic analgesics for colitis with perfora-
per day pain of >2 weeks tion or life-
threatening
bleeding; or >2-
week duration of
more than 12
stools per day
4. Fatal - Fatal Fatal
Table IV Patients change in Karnofsky performance score
After treatment (months)
KPS Before treatment 1 2 4 6
Regimen A B A B A B A B A B
<50* 1 - 2 1 2 2 4 5 6 6
60, 70 3 8 4 4 5 5 3 4 2 -
>80 6 5 4 8 3 6 3 4 2 5
'Includes patients dying
Table V Patient's change in respiratory score
After treatment (months)
RS Before treatment 1 2 4 6
Regimen A B A B A B A B A B
4,5* 1 3 2 1 3 3 3 5 7 7
3 5 - 2 - 3 - 3 - 3
1,2 9 5 8 10 7 7 7 5 3 3
Grade 1, 2 climb hills, stairs, walk any distance on the flat at normal
pace, without dyspnoea; Grade 3, 4 walks more than 100 yards at own
speed without dyspnoea, dyspnoea on walking 100 yards or less; Grade
5dyspnoea onmildexertion, e.g. undressing (dyingpatients included).*
(MRC Lung Cancer Working Party - 1979).
there was no bronchopneumonia, but tumour was involving
the oesophagus, pericardium, mediastinum, left hilum and
left lower lobe.
Discussion
The maximum tolerated doses (MTD) identified in the pre-
sent study were as follows. Cyclophosphamide 5 G m-2 given
twice (i.e. 10 G total) in a 24 h period, ifosfamide 11 G m-2
given as an infusion over 24 h, mustine 30 mg m-2 total
again given on two occasions within a 24 h period and
mitomycin C as a 24 h infusion of 70 mg m-2. The cisplatin
(total dose of 100 mg m-2) was given on two occasions with-
in a 24 h period with fluid diuresis and close monitoring of
the urine output. These values can be compared with pre-
vious reports of MTDs for mustine of 30mgm2, higher
doses were said to be associated with neurotoxicity and
cardiotoxicity and mitomycin C 60 mg m-2 higher doses
being associated with veno-occlusive disease and haemorr-
hagic colitis although toxicity was somewhat reduced by
infusions. Cyclophosphamide at high dose (> 160 mg kg-')
has been associated with haemorrhagic myocarditis when
used in combination with other agents (Postmus & de Vries,
1984). Data on ifosfamide are available from our previous
study in melanoma in which two doses, each of 4 G m-2 in a
24h period could be safely administered (Thatcher et al.,
1989). Recently other studies have examined cisplatin in com-
bination with cyclophosphamide and BCNU and have identi-
fied MTDs of 5.6 G m-2 for cyclophosphamide and 165 mg
m-2 for cisplatin which are approximately 6-fold and 1.5-fold
greater than standard doses (Peters et al., 1986).
Non small cell lung cancer has been examined previously
in five patients who were part of larger studies including a
variety of solid tumours, investigating single agent high dose
chemotherapy with ABMR. In these five patients there were
two responses and in another eight patients treated with high
dose combination chemotherapy, there were six partial remis-
sions (Cheson et al., 1989). The agents used in these studies
would not be considered to be particularly effective in
NSCLC. The only study addressing the subject in some detail
was of 15 patients with stage IV NSCLC treated with cyclo-
phosphamide (7.5 G m-2 over 3 days) with thiotepa escalated
from 1.8 mg kg-' to 6.0mg kg-' also over 3 days. A further
seven patients received oral melphalan, 0.75 mg kg-' to
2.5mg kg-' over 3 days (Williams et al., 1989). Of the 13
evaluable patients in this study, there were no complete
responders and seven (47%) obtained a partial response with
a median duration of 3 months. There was significant non-
haematological toxicity involving the GI tract, haemorrhagic
cysitits and cardiomyopathy.
The current study of 23 patients demonstrated that higher
doses of the more active agents in NSCLC can be given
without overwhelming non-haematological toxicity. In partic-
ular there was no evidence of veno-occlusive disease of the
liver nor of colitis, encephalopathy, cardiomyopathy. The
avoidance of these non-haematological dose limiting tox-
icities is clearly due to multiple factors, for example a reason-
ably good performance status, the lack of abnormal liver
function, renal function before treatment, the use of infusion
therapy and possibly the support with selenium and other
trace elements could have prevented the colitis and haemorr-
hagic myocarditis (Thatcher et al., 1989). The marrow
recovery within 3 weeks despite these high doses is likely to
be due to the marrow rescue programme. There was no
evidence that the higher doses were associated with longer
recovery times or greater myelosuppression suggesting that
bone marrow support did contribute to recovery from myelo-
suppression. There was no evidence of refractory thrombo-
cytopaenia although this has been reported previously (Peters
et al., 1986).
Although a very gratifying response rate with five complete
responders was observed, as in other studies of refractory
tumours the overall median duration of response was short.
The study did demonstrate that higher than expected respon-
ses could be obtained albeit in a young and fitter population
compared with most NSCLC patients, but with only a min-
ority surviving more than 1 year. However, there were three
deaths which could be ascribed to treatment which is similar
to other reports of high dose combination therapy (Peters et
al., 1986).
As suggested for breast cancer it could be possible to
consider an intensive approach after remission has been
obtained with combinations of the most active agents inHIGH DOSE CHEMOTHERAPY FOR NSCLC 297
NSCLC e.g. ifosfamide, cisplatin, mitomycin C. The lack of
substantial non-haematological toxicity suggests that the ap-
proach might be feasible in a selected group of patients with
advanced NSCLC. The requirement for ABMR may also be
offset by the use of haematological growth factors (Bronchud
et al., 1987). Nevertheless the single high dose strategy de-
scribed in the current report had no survival advantage over
conventional dosages of the same agents previously used in
metastatic NSCLC.
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